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Design, synthesis, molecular docking and ADME
studies of novel indole-thiazolidinedione
derivatives and their antineoplastic activity
as CDK6 inhibitors†
Zeynep Ates-Alagoz, *a Mehmet Murat Kisla,a Fikriye Zengin Karadayi,a
Sercan Baran,a Tuğba Somay Doğanb and Pelin Mutlub
Several 5-((5-substituted-1H-indole-3-yl)methylene)-3-(2-oxo-2-(3/4-substituted-phenylethyl)-thiazolidine-
2,4-dione derivatives (9–24) were designed and synthesized as CDK6 inhibitors, and their anticancer activity
was probed on the MCF-7 breast cancer cell line and their effects on gene expression profiles were
elucidated. According to biological activity assays, compounds 10, 15, and 18 were found to possess
favorable cytotoxicity on this cell line. For a better understanding of their activity rationale, genomic studies
were conducted. Changes in gene expression levels occurring in MCF-7 cells were studied on 48 genes
selected among genes associated with the estrogen receptor, tumor suppressor and oncogenes,
microtubule formation, apoptosis, the cell cycle, drug resistance and inflammation. It was determined that
there are significant differences in gene expression levels in 21 of these genes. Comparing to other genes,
these compounds inhibited gene expression of CDK6 much more. For a more thorough evaluation of their
mechanism of action involving this pathway, docking analysis was performed with a corresponding enzyme
that is synthesized by the CDK6 gene. By doing so, the binding profiles of these derivatives were compared
to the reference study. In the end, the impact of the indole-thiazolidinediones on CDK6 and their
mechanisms of action were elucidated. Compounds 15 and 18 possess higher affinity with better binding
interactions relative to that of compound 10. These two compounds were highlighted as possible
candidates for upcoming design studies of CDK6 inhibitors. Moreover, the druglikeness of the indole-
thiazolidinediones was calculated and compared to commercial anticancer drugs.
1. Introduction
Breast cancer (BC) has become a major mortality reason in
women all over the world. In the medical literature, BC is
classified into four subtypes, luminal A (HR+/HER2); HER2+;
luminal B (HR+/HER2+); and triple-negative (TNBC; HR/
HER2). Each of these subtypes has different risk factors, disease
progression, metastasis profiles, and therapeutic responses.1
Cyclin-dependent kinase 6 (CDK6) has become a valid target
for breast cancer therapy over the past decades. This class of
proteins constitutes a major family of regulatory enzymes that
modify the cell cycle and cellular division mechanisms.2–5
Retinoblastoma protein (Rb) is a tumor suppressor unit that
monitors the transition from the G1 to the S phase.6 This
protein binds the E2F transcription factors to halt the G1/S
transition, and thus controls early cell division. Inhibition of
Rb, on the other hand, permits cell division to continue.7 In the
G1 phase, cyclin D may bind to CDK4 or CDK6 and cause
phosphorylation of Rb and with the eventual release of E2F the
cell cycle would proceed.6 Therefore, the CDK4/6-Rb axis plays a
key role in many malignancies such as estrogen receptor-
positive BC. In this malignancy, estrogen increases the rate of
transition from the G1 to the S phase.8–10 Activation of ER-alpha
by estrogen eventually leads to the activation of CDK4/6 and
phosphorylation of Rb, and thus subsequent cell cycle
progression.11–13 Thereby, selective inhibition of CDK4/6 would
lead to cell cycle arrest in the G1 phase, resulting in cell death
and a reduced tumor response. Recent scientific investigations
have led to a novel drug class of cyclin-dependent kinase (CDK)
4/6 inhibitors, which have been employed for the treatment of
HR+ and HER2 advanced breast cancer types in different
combined therapies.14–19 These combinations with drugs that
block downstream estrogen-dependent cancer cell stimulation
a Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Ankara University,
Ankara, Turkey. E-mail: zeynep.ates@pharmacy.ankara.edu.tr
b Central Laboratory, Molecular Biology and Biotechnology R&D Center,
Middle East Technical University, Ankara, Turkey
† Electronic supplementary information (ESI) available. See DOI: 10.1039/
d1nj02808a
Received 8th June 2021,







































































New J. Chem. This journal is © The Royal Society of Chemistry and the Centre National de la Recherche Scientifique 2021
can enhance the activity of CDK4/6 inhibitors. Inhibition of the
estrogen pathway results in reduced complexation of CDK4 and
CDK6.20 The combination therapy of palbociclib, ribociclib,
and abemaciclib with aromatase inhibitors or fulvestrant is
therefore used for the treatment of HR+ and HER2 breast
cancer.21–23
The interest in the antiproliferative effect of the indole core
has increased in recent years and this ring system constitutes
some of the known anticancer drugs such as vinblastine
sulfate, vincristine sulfate, vinorelbine sulfate, and vindesine
sulfate, and crucial bioactive compounds such as melatonin,
serotonin, and tryptophan.24–27 Much like the indole ring, the
thiazolidine ring system has also been employed in many anti-
cancer drug development studies. Similarly, the medicinal
importance of the 2,4-thiazolidinedione scaffold was under-
lined by Sethi et al. with two studies.28,29 For example, several
thiazolidinedione compounds were screened in a galactose
media MCF-7 cell model for probing mitochondria-related
cytotoxicity. In the end, a thiazolidine (IC50 = 7.1 mM) and its
unsaturated derivative (IC50 = 3.3 mM) were found to possess
favorable IC50 values.
30 In another study, Yadav et al. designed
phenanthrene-thiazolidinedione hybrid derivatives from the
Knoevenagel condensation of phenanthrene-9-carbaldehyde
and N-alkylated thiazolidinediones and analyzed their anti-
proliferative effects against various human cancer cell lines,
and discovered a compound with good cytotoxic activity that
also causes apoptotic morphological changes. According to the
flow cytometry analysis, cell cycle arrest at the G0/G1 phase has
occurred in these cells in a dose-dependent manner.31 In another
study, Sigalappalli et al. recently fused 4-thiazolidinone, which has
anticancer activity patterns through several mechanisms,32–38
with indole into one united structure and assessed the anticancer
activity of this motif against different cell lines. Overall, some of
the synthesized derivatives exhibited excellent anti-proliferative
activity and a favorable ADME (absorption, distribution, meta-
bolism, and excretion) profile.39 Similarly, we implemented a
hybridization scheme that involves connecting indole-3-carbox-
aldehyde with a thiazolidinedione ring at the fifth carbon of the
thiazolidinedione ring. According to the design rationale from
the Sigalapalli study, the thiazolidinone ring is crucial for its
capacity to perform hydrogen bonding and various substitu-
tions were made at the indole nitrogen. We have substituted
the free nitrogen at the core and changed the substituted imine
group with a oxo group. Since hydrogen bonding was impor-
tant, we have removed the alkyl group at the indole moiety, for
increasing the activity. A comparison between the main struc-
tures from the study by Sigalappalli et al. (1) and this study (2) is
outlined in Fig. 1.
To this end, several indole-thiazolidinediones were synthe-
sized and their anticancer activities were evaluated on the MCF-7
cell line. Moreover, the mechanism of action for the compounds
was identified with the following docking analyses. In this pro-
cess, interacting residues and distances and the docking energy
were determined and interpreted. Additionally, pharmacokinetic
parameters and the drug-likeness of the synthesized compounds
and commercial anticancer drugs were calculated. By using these
approaches, the anticancer activity profiles of the indole-
thiazolidinediones and the importance of the CDK6 enzyme were
investigated.
2. Results
2.1. Anti-cancer activity on the MCF-7 cell line
2.1.1. Cytotoxicity analysis. The cytotoxic effects of the 16
synthesized compounds were analyzed on the MCF-7 cell line
using an xCELLigences Real Time Cell Analyzer for 72 hours.
The cells were treated with three different concentrations
(5 mM, 50 mM, and 100 mM) of the compounds. Vincristine is
widely used in breast cancer threapy and known as an effective
tubulin polimerase inhibitor. Our compounds have similar
molecular structures to vincristine and at the beginning of
our study we want to compare the cytotoxic effects of our
compounds with vincristine and use it as a positive control.
In this way we have determined the most toxic ones with
respect to vincristine. The IC50 value for this compound was
found to be 1 mM. The candidate compounds 10, 15, and 18,
which were found to have a significant cytotoxic effect when
compared to vincristine, were selected and further studies were
continued with these three compounds (Table 1).
Fig. 2 shows the antiproliferative effect of the selected
compounds on MCF-7 cells. The degree of cytotoxicity was
determined by measuring the IC50 values at 72 h. With the
MCF-7 cell line, compound 10 killed 50% of the cells at a dose
of 3.14 mM. This value was 8.52 mM and 14.60 mM for compound
15 and compound 18, respectively. The IC50 value for vincris-
tine was 1 mM. These results show that in comparison to our
positive control vincristine, compound 10 shows the most
cytotoxic effect on MCF-7 cells.
2.1.2. Gene expression analysis. Table 2 summarizes the
alterations in expression levels of the genes in vincristine, and
compound 10, 15, and 18 treated MCF-7 cells.
The synthesized compounds and vincristine were exposed to
MCF-7 cells at their IC50 doses for 72 hours, and changes in
expression levels were studied among 48 selected genes related
to the estrogen receptor, tumor suppressor and oncogenes,
microtubule formation, apoptosis, the cell cycle, drug resis-
tance, and inflammation. Significant differences were found in
the gene expression levels in 21 of these 48 genes.
Fig. 1 A comparison between the design strategies of the indole-
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When compared with vincristine selected as a positive control,
compounds 10 (13 genes in 21) and 18 (12 genes in 21) were found
as generally closer to vincristine in terms of gene expression
changes. It has been determined that compound 15 (6 genes
in 21) causes different gene expression changes than vincristine.
When looking at gene expression related to microtubule regulation,
it was found that vincristine reduced TUBD1 and MAP4 gene expres-
sion approximately 181 times. The expression of these genes is
reduced about 2 times by compound 18. It was determined that there
was no significant change depending on the application of 10 and 15.
Table 1 Effective dose range of the 16 synthesized compounds at low, medium and high doses on the MCF-7 cell line with respect to vincristine
Compound R1 R2 5 mM 50 mM 100 mM Toxicity range (mM) Selected compounds*
,**,***
Vincristine Toxic Toxic Toxic 1 Positive control
9 H Nontoxic Toxic Toxic 10–50
10* OCH3 Nontoxic Toxic Toxic 1–5 Most toxic*
11 Cl Nontoxic Toxic Toxic 10–50
12 Br Positively induced Toxic Toxic 20–50
13 H Nontoxic Toxic Toxic 10–50
14 OCH3 Nontoxic Toxic Toxic 10–50
15** Cl Toxic Toxic Toxic 5–10 Second most toxic**
16 Br Nontoxic Toxic Toxic 10–50
17 OCH3 Nontoxic Toxic Toxic 50–100
18*** Cl Nontoxic Toxic Toxic 10–50 Third most toxic***
19 Br Nontoxic Toxic Toxic 10–50
20 H Nontoxic Toxic Toxic 10–50
21 H Nontoxic Toxic Toxic 10–50
22 Cl Nontoxic Toxic Toxic 10–50
23 Br Nontoxic Toxic Toxic 10–50
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The MCF-7 breast cancer cell line is an estrogen receptor-
positive cell line. Estrogen binding to these receptors enables
cancer cells to survive. It was found that the ESR1 gene
expression was decreased 170-fold due to vincristine adminis-
tration. Similarly, as a result of the administration of compounds
10 and 15, a 3 and 5 fold decrease in ESR1 gene expression was
found, respectively.
While there was a significant decrease in BRCA1, RB1, and
TP53 tumor suppressor gene expression due to vincristine
treatment, a significant increase was found in the expression
of these genes in 15 treated MCF-7 cells. This shows that 15 can
create a cytotoxic effect on MCF-7 cells by increasing tumor
suppressor genes, unlike vincristine. When we examine the
gene expression related to apoptosis, it was found that BIRC3,
one of the anti-apoptotic genes, decreased significantly due to
the application of all three compounds with vincristine.
It was determined that Bcl-2, one of the other anti-apoptotic
genes, decreased due to vincristine and 18 application, and
MCL1 decreased only due to vincristine application. PDCD10
and CASP9, which are among the apoptotic genes, have been
found to increase only after application of 15. These results
indicate that compound 15 tends to lead the cell to apoptosis by
increasing apoptotic gene expression, unlike vincristine.
When we look at the genes related to the cell cycle, we see
that vincristine decreases CDK4 (11-fold) and CDK6 (9-fold)
gene expression. It was found that compounds 15 and 18
reduced CDK6 expression by about 7 and 10 times, respectively.
There was a 1.6-fold decrease in the expression of both of these
genes for compound 10.
It was found that STAT1 gene expression, which controls the
IL-17 pathway, which is one of the genes involved in inflamma-
tion, decreased due to the treatment with vincristine and 15,
but the treatment with compounds 10 and 18 significantly
increased the expression of this gene.
Finally, it was seen that the expression of the ABCG2 and
ABCC1 genes, which we have examined for the development
of drug resistance, decreased due to vincristine application.
However, it was noteworthy that the ABCC1 gene expression
increased 5 times only due to compound 15 application. The
increase in ABCC1 gene expression due to treatment with 15
Fig. 2 Antiproliferative effect of compounds (A) 10, (B) 18 and (C) 15 on MCF-7 cells.
Table 2 Fold changes in gene expression levels with respect to the nontreated MCF-7 control group
Gene
Control
Vincristine Compound #10 Compound #15 Compound #18
Ct Ct Fold change–2DDCt Ct Fold change–2DDCt Ct Fold change–2DDCt Ct Fold change–2DDCt
TUBD1 32.50 40.00 181 33.89 1.31 32.74 +1.69 34.52 2.02
MAP7 30.40 30.71 1.23 31.46 1.04 29.92 +2.78 29.99 +2.65
MAP1B 32.00 31.72 +1.21 32.95 +1.03 33.03 1.02 31.08 +3.78
MAP4 31.50 39.00 181 32.82 1.25 32.07 +1.34 33.25 1.68
ABCG2 32.63 40.00 165 34.02 1.31 32.98 +1.56 34.16 1.44
ESR1 32.59 40.00 170 35.06 2.77 36.01 5.35 33.40 +1.14
BIRC3 33.35 37.44 17 36.60 4.75 37.00 6.27 38.00 12.55
STAT1 32.47 38.03 47 31.17 +5.09 37.00 11.55 28.97 +22.6
NOTCH1 33.46 34.56 2.14 33.62 +1.79 33.56 +1.86 34.00 +1.37
MYC 30.88 39.00 278 31.21 +1.59 30.87 +2.01 37.18 39
PDCD10 34.28 33.87 +1.32 35.10 +1.13 34.20 +2.11 34.75 +1.44
BCL2 30.07 36.37 79 31.23 1.07 30.21 +1.86 38.00 119
TP53 26.87 29.98 8.6 27.36 +1.4 25.67 +4.6 28.53 1.5
CASP9 34.09 39.00 30 34.69 +1.3 33.53 +3 34.33 +1.74
RB1 31.76 36.14 20 32.80 1 31.78 +2 32.63 +1.14
CDK4 29.30 32.75 11 30.96 1.6 30.24 +1.1 30.84 1.4
CDK6 33.25 36.44 8.5 34.95 1.6 37.00 6.5 37.60 9.8
ABL1 31.62 31.22 +1.3 32.72 1.1 31.59 +2 31.99 +1.5
MCL1 34.97 39.00 16 34.23 +3.5 34.30 +3 33.08 +7.5
ABCC1 34.59 37.58 8 35.64 1 33.23 +5 34.65 +1.86
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indicates that MCF-7 cells may become susceptible to developing
resistance by expelling this compound from the cell.
2.2. Validation of the docking process
Validation of this docking pipeline with CDK6 was implemen-
ted according to the method in Section 5.2, by using two
approaches: the first one was comparing the binding poses
and interaction patterns and the second approach was calcula-
ting the RMSD between the two poses of palbociclib. In the end,
the comparison was rather fruitful since we witness nearly
identical interactions. The relevant comparison of the interac-
tions is given in Fig. 3 and the calculated RMSD value was
0.5519, whereas the threshold value is 2.00 for a reliable docking
process. The process was thus validated after obtaining an
acceptable value below this limit. From now on, it was safe to
proceed onwards to the docking process.
2.3. Docking results
By the guidance of the activity results obtained against the
MCF-7 cell line, compounds 10, 15, and 18 were identified as
the greatest suppressors of the CDK6 gene. To spotlight and
elaborate this phenomenon, docking analysis of these ligands
with the CDK6 protein was implemented. As a starting point, an
interaction pattern from the reference study was utilized and
thus the necessary amino acids were determined.40 The valida-
tion process that we conducted confirmed these interactions.
At this point, the residues in Fig. 4 were used as a baseline for
interaction interpretations.
Three potent suppressors of the CDK6 gene were probed in
the docking analysis to confirm their interaction with this
enzyme, which would conclude with cell cycle arrest, thus
causing a cytotoxic effect on cells. According to Fig. 4, these
ligands have docked perfectly to the binding site. The least
potent suppressor compound 10 (affinity = 8.5 kcal mol1)
also had the lowest number of interactions. It gave a carbon–
hydrogen bond interaction with Gln149 (3.53 Å). On the other
hand, compound 15 (affinity = 8.8 kcal mol1) gave many
more hydrophobic interactions to stabilize and two hydrogen
bond interactions with Asn150 (3.00 Å) and Tyr24 (2.35 Å).
It also exhibited a carbon–hydrogen bond with Gly20 (3.47 Å).
Compound 18 (affinity = 8.6 kcal mol1) gave a greater
number of hydrogen bond interactions such as conventional
H-bonds with Gln149 (2.25 Å), and Lys147 (2.85 Å), and carbon–
hydrogen bonds with Ile19 (3.47 Å) and Gly20 (3.27 Å). These
interaction diagrams confirm the gene suppressing activity of
indole-thiazolidinedione derivatives 10, 15, and 18. Further-
more, the difference in the interacting amino-acid numbers
may be the reason for the variation between their activities
against the CDK6 gene.
2.4. Assessment of ADME properties
For the manifestation of the anti-cancer activity, drug molecules
have to permeate through certain barriers in the organism. To this
end, compounds need to possess favorable biopharmaceutical
properties. The drug-likeness of compounds 9–24 was compared
with commercial drug molecules with the aid of physicochemical
parameters and ADMET determination. Thus, predicting their
behaviour against certain barriers such as the blood brain barrier
and gastrointestinal tract has become much easier.
According to Table 3, the majority of the indole-thiazo-
lidinedione derivatives have passed Lipinski’s rule of five.
Palbociclib, which is a known selective CDK4/6 inhibitor, has
satisfied Lipinski and has inhibited only one of the CYP-450
enzyme family. According to the calculations, this compound
does not permeate through the blood–brain barrier (BBB) and
is a substrate for P-glycoprotein, which makes it a nearly ideal
drug. In contrast, Vinca derivatives have failed to abide by
Lipinski and other rules. This may be due to their natural
product characteristics. Excluding some deviant values, the
log P profiles were similar. Compound 23 has the highest log P
value in the set. This parameter has a great impact on the
ADME and drug-likeness of an active compound. Additionally,
a high log P value means an eventual formulation impediment
regarding its solubility in water while greatly influencing
absorption and elimination. This excessively high log P value
of 23 can also cause central nervous system side effects and
thus should be considered as a selectivity problem. The topo-
logical polar surface area is literally defined as the surface area
of the compound which makes contact with the solvent. Therefore
this value has an impact on bioavailability. Since colchicine has a
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relatively lower molecular volume compared to that of Vinca
alkaloids, this value was also found to be lower. The permeability
through the blood–brain barrier was evaluated to identify possible
CNS side effects of the indole-thiazolidinedione derivatives. It is
clear that none of the derivatives tend to permeate through this
barrier, and thus theoretically should have no side effects.
P-Glycoprotein is a protein that is responsible for the excretion
of chemicals from the cell membrane. Longer residence in the cell
leads to longer action, and therefore long-acting drug molecules
need to avoid being a substrate for this enzyme. In Table 3,
commercial derivatives would become substrates, while our
indole-thiazolidinedione derivatives tend to bypass this enzyme.
This phenomenon may create a remarkable bioavailability differ-
ence between these derivatives. Furthermore, CYP-450 enzyme
inhibition was evaluated. Compounds 17, 18, and 19 inhibit the
lowest number of members in this enzyme family and thus
become rather safe candidates regarding drug interactions.
Overall, compounds 17 and 18 would be the most versatile ones
since they would not pass the blood–brain barrier, thus having no
CNS side effects. Also, they do not possess the ability to become
P-glycoprotein substrates, which leads to a bioavailability boost.
Evidently, these two compounds perfectly satisfy Lipinski. Since
they also have lesser affinity to CYP-450 enzymes, they would not
cause corresponding drug interactions.
3. Discussion
Indole derivatives are known to be associated with signi-
ficant activity against breast cancer cells including induction
of apoptosis, disturbing tubulin assembly, inhibition of the
NFkB/mTOR/PI3K/AkT pathway, regulation of estrogen-mediated
activity and modulation of critical targets such as topoisomerase
and HDAC.41
Fig. 4 Aligned binding poses of the indole-thiazolidinedione derivatives 10, 15, and 18 in the CDK6 binding site from two different angles (A and B).
Below the first image, the interaction patterns of the three indole-thiazolidinedione ligands were presented. Green interactions depict conventional
H-bond interactions whereas light green is for carbon hydrogen bonding. Light pink, dark pink and magenta are for steric interactions. Finally, the orange
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On the other hand, thiazolidinediones (TZDs) have been
shown to possess antitumoral properties in different human
cancers including breast cancer. TZDs bind and activate the
peroxisome proliferator-activated receptor (PPAR)-g, which is a
nuclear receptor acting as a transcription factor in several
tissues.42 In the literature it was shown that TZDs increased
the number of H295R (Human Adrenocortical Cancer Cell Line)
cells in the G0/G1 phase and decreased them in the S phase,
increasing the expression of the cell cycle inhibitors p21 and
p27 and reducing the expression of cyclin D1.43
In this study, a synthesis strategy of anticancer compounds
involving the fusion of indole and thiazolidinedione nuclei was
taken as a basis. The synthetic procedure of the indole-
thiazolidinedione derivatives is shown in Scheme 1. Because
of the labile hydrogen atom at the 3-position, thiazolidine-2,4-
dione was N-alkylated with appropriate phenacyl halides in
alkaline medium. The condensation of N-phenacyl inter-
mediates 2–7 with indole carboxaldehyde in MeOH and in the
presence of diethanolamine by a Knoevenagel reaction led
to 5-((5-substituted-1H-indole-3-yl)methylene)-3-(2-(substituted-
phenyl)-2-oxoethyl)-thiazolidine-2,4-dione derivatives (9–24).
In the drug active substance design phase, primarily the
tubulin polymerase protein was selected as the biological
target, and suitable candidates for synthesis were determined
among the designed compounds. Vincristine, a renowned
tubulin polymerase inhibitor bearing the indole structure,
was used as a positive control for cytotoxicity and gene expres-
sion analysis. Among the synthesized 16 compounds (9–24),
10 (carrying methoxyl in the indole ring like melatonin), 15
(R1, R2 = Cl), and 18 (R1 = NO2, R2 = Cl) were found as the
most prominent cytotoxic ones on MCF-7 breast cancer cells.
According to gene expression studies, it was determined that in
general the gene expression changes in the MCF-7 breast cancer
cell line were closer to vincristine for compounds 10 and 18.
Although the cytotoxic activities of the indole-thiazolidinedione
derivatives and their association with the genes related to
microtubule regulation, TUBD and MAP4, were found to be
low, they have more effect on tumor suppressor, cell cycle and
apoptosis-related genes.
Among these genes CDK6, which has an important function
during the cell cycle, took our attention since vincristine,
compound 15, and compound 18 reduced its expression values
9-fold, 7-fold and 10-fold, respectively. There was a 1.6-fold
decrease in CDK6 expression for compound 10. Therefore,
these compounds were probed against CDK6 in docking stu-
dies to understand their interaction fingerprints and binding
profiles. In this study, docking interactions of compounds 10,
15, and 18 with CDK6 were investigated. Compounds 15 and 18
offered higher affinity values and better interaction profiles
with more hydrogen bonds and more stabilization in the cavity.
After consulting these findings, we were able to confirm and











enzymes (out of 5) Lipinskia
Palbociclib 2.20 105.04 0 1 1 1
Vincristine 3.41 171.17 0 1 1 0
Vinblastine 3.77 154.10 0 1 1 0
Vinorelbine 4.13 133.87 0 1 1 0
Colchicine 2.33 83.09 0 1 2 1
9 2.77 91.78 0 0 4 1
10 2.73 101.01 0 0 4 1
11 3.29 91.78 0 0 4 1
12 3.29 91.78 0 0 4 1
13 3.30 91.78 0 0 4 1
14 3.27 101.01 0 0 4 1
15 3.84 91.78 0 0 4 1
16 3.89 91.78 0 0 4 1
17 2.08 146.83 0 0 3 1
18 2.53 137.60 0 0 3 1
19 2.62 137.60 0 0 3 1
20 2.79 101.01 0 0 4 1
21 3.81 91.78 0 0 4 1
22 4.32 91.78 0 0 4 1
23 4.41 91.78 0 0 4 1
24 3.04 91.78 0 0 4 1
a Yes or satisfying the criteria is represented by 1 while 0 is used for defining ‘‘no’’ or not satisfying that rule.
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understand the CDK6-suppressing mechanisms of these potent
derivatives.
The results of this study can be significant since there are
supportive data in the literature that show one of the indole
and thiazolidinedione-containing compounds has an effect
on suppression of CDK6 expression. Cram et al. showed that
indole-3-carbinol (I3C) can induce a G1 cell cycle arrest of
human MCF-7 breast cancer cells that is accompanied by the
selective inhibition of cyclin-dependent kinase 6 (CDK6)
expression.44
In addition, the I3C-mediated cell cycle arrest and repres-
sion of CDK6 production were also observed in estrogen
receptor-deficient MDA-MB-231 human breast cancer cells,
which demonstrates that this indole can suppress the growth
of mammary tumor cells independent of estrogen receptor
signaling, which implicates CDK6 as a target for cell cycle
control in human breast cancer cells.45
On the other hand, there are also studies that show the
effect of thiazolidinedione on Cdk6 expression in breast cancer.
Dose-dependent application of thiazolidinedione causes growth
inhibition, G1 arrest, and apoptotic death of MDA-MB-231 cells by
decreasing the expression levels of pRb, cyclin D1, cyclin D2,
cyclin D3, Cdk2, Cdk4, and Cdk6 genes.46
4. Experimental part
4.1. Synthetic procedures
The synthesis of the compounds was carried out as shown
in Scheme 1. Compounds 1–7 were prepared according to
the literature.47–51 5-Methoxy-indole-3-carboxaldehyde (8) was
obtained by direct formylation of indole with dimethylform-
amide, using phosphorous oxychloride as a catalyst.52 Other
derivatives indole-3-carboxaldehyde, 5-chloro-indole-3-carbox-
aldehyde, and 5-bromo-indole-3-carboxaldehyde (Aldrich) were
procured commercially.
4.1.1. General procedure for synthesis of 9–24. Compounds
9–24 were prepared according to general methods starting from
the reflux of appropriate indole-3-carboxaldehyde (1 mmol) and
phenacyl-methyl-thiazolidine-2,4-dione (1 mmol) in MeOH and
diethanolamine for 2 h (determined by TLC with n-hexane:ethyl
acetate 2 : 1). The mixture was cooled and water was added and
the formed precipitate was filtered and washed. The residue
was crystallized with dichloromethane and EtOH to give the
products.47
4.1.1.1. (E/Z)-5-((1H-Indole-3-yl)methylene)-3-(2-oxo-2-phenylethyl)-
thiazolidine-2,4-dione (9). Compound 9 was prepared according
to the general method starting from 3-(2-oxo-2-phenylethyl)-
thiazolidine-2,4-dione (0.85 mmol, 0.2 g) and indole-3-carbox-
aldehyde (0.85 mmol, 0.123 g). Rf: 0.48, m.p. 283–285 1C,
(0.154 g, 77% yield). FTIR (KBr, n, cm1): 3378, 1729, 1697,
1658, 1591. 1H NMR (400 MHz, DMSO-d6): d ppm 5.27 (s, 2H),
7.18–7.28 (m, 2H), 7.51–7.61 (m, 3H), 7.73 (t, 1H), 7.87 (s, 1H),
7.92 (d, J = 7.6 Hz, 1H), 8.07–8.09 (m, 2H), 8.24 (s, 1H), 12.24
(brd s, 1H). 13C NMR (DMSO-d6): d ppm 47.72, 110.39, 112.47,
113.21, 118.46, 121.24, 123.20, 126.49, 126.78, 128.23, 129.02,
129.36, 133.86, 134.38, 136.26, 165.11, 166.88, 191.53. MS (ESI+)
m/z: 363. Anal. calcd for C21H19Cl2N3O2S: C, 66.28; H, 3.89;
N, 7.73; S, 8.85; found: C, 65.77; H, 3.81; N, 7.76; S, 8.70.
4.1.1.2. (E/Z)-5-((5-methoxy-1H-indole-3-yl)methylene)-3-(2-oxo-
2-phenylethyl)-thiazolidine-2,4-dione (10). Compound 10 was
prepared according to the general method starting from 3-(2-
oxo-2-phenylethyl)-thiazolidine-2,4-dione (0.85 mmol, 0.2 g) and
5-methoxy-indole-3-carboxaldehyde (0.85 mmol, 0.148 g). Rf =
0.37, m.p. 247–249 1C (0.100 g, 50% yield). FTIR (KBr, n, cm1):
3274, 1729, 1694, 1658, 1587. 1H NMR (400 MHz, DMSO-d6): d
ppm 3.83 (s, 3H), 5.29 (s, 2H), 6.88 (dd, J = 8.6 Hz, J = 2.4 Hz, 1H),
7.42 (d, J = 9.2 Hz, 1H), 7.49 (d, J = 2.4 Hz, 1H), 7.60 (d, J = 7.2 Hz,
1H), 7.63 (s, 1H), 7.73–7.77 (m, 1H), 7.80 (s, 1H), 8.10 (d, J =
7.2 Hz, 2H), 8.29 (s, 1H), 12.11 (brd s, 1H). 13C NMR (DMSO-d6):
d ppm 47.70, 55.47, 100.27, 110.46, 112.36, 113.25, 113.47,
127.05, 127.70, 128.23, 129.02, 129.48, 131.08, 133.89, 134.38,
155.10, 165.10, 166.94, 191.56. MS (ESI+) m/z: 393. Anal. calcd for
C21H16N2O4S-0.4H2O-0.3CHCl2: C, 60.22; H, 4.05; N, 6.59; S, 7.54;
found: C, 60.29; H, 4.26; N, 6.75; S, 7.68.
4.1.1.3. (E/Z)-5-((5-chloro-1H-indole-3-yl)methylene)-3-(2-oxo-
2-phenylethyl)-thiazolidine-2,4-dione (11). Compound 11 was
prepared according to the general method starting from 3-(2-
oxo-2-phenylethyl)-thiazolidine-2,4-dione (0.85 mmol, 0.2 g) and
5-chloro-indole-3-carboxaldehyde (0.85 mmol, 0.152 g). Rf = 0.37,
m.p. 249–251 1C (0.110 g, 55% yield). FTIR (KBr, n, cm1): 3352,
1725, 1690, 1656, 1582. 1H NMR (400 MHz, DMSO-d6): d ppm
5.29 (s, 2H), 7.25 (dd, J = 8.4 Hz, J = 2.4 Hz, 1H), 7.52 (d, J =
8.8 Hz, 1H), 7.59 (d, J = 7.6 Hz, 1H), 7.62 (s, 1H), 7.74 (t, 1H), 7.91
(s, 1H), 8.08 (d, J = 7.2 Hz, 3H), 8.26 (s, 1H), 12.37 (s, 1H).
13C NMR (DMSO-d6): d ppm 47.74, 110.21, 113.99, 114.04,
118.27, 123.21, 125.96, 126.26, 128.06, 128.23, 129.02, 130.47,
133.85, 134.38, 134.72, 164.98, 166.77, 191.50. MS (ESI) m/z:
395. Anal. calcd for C20H13ClN2O3S: C, 60.53; H, 3.30; N, 7.06; S,
8.08; found: C, 60.42; H, 3.33; N, 7.17; S, 8.15.
4.1.1.4. (E/Z)-5-((5-Bromo-1H-indole-3-yl)methylene)-3-(2-oxo-
2-phenylethyl)-thiazolidine-2,4-dione (12). Compound 12 was
prepared according to the general method starting from 3-(2-
oxo-2-phenylethyl)-thiazolidine-2,4-dione (0.85 mmol, 0.2 g)
and 5-bromo-indole-3-carboxaldehyde (0.85 mmol, 0.190 g).
Rf = 0.33, m.p. 263–265 1C (0.230 g, 72% yield). FTIR (KBr,
n, cm1): 3360, 1723, 1690, 1656, 1580. 1H NMR (400 MHz,
DMSO-d6): d ppm 5.29 (s, 2H), 7.19–7.28 (m, 2H), 7.52 (d, J =
8.0 Hz, 1H), 7.67 (dd, J = 6.8 Hz, J = 1.2 Hz, 2H), 7.87 (s, 1H),
7.92 (d, J = 7.2 Hz, 1H), 8.10 (dd, J = 6.8 Hz, J = 1.2 Hz, 2H), 8.23
(s, 1H), 12.25 (s, 1H). 13C NMR (DMSO-d6): d ppm 47.67, 110.38,
112.47, 113.14, 118.45, 121.24, 123.20, 126.55, 126.78, 129.15,
129.38, 130.18, 132.55, 136.25, 139.33, 165.05, 166.86, 190.79. MS
(ESI+) m/z: 443. Anal. calcd for C20H13BrN2O3S: C, 54.43; H, 2.97;
N, 6.35; S, 7.27; found: C, 54.08; H, 2.97; N, 6.45; S, 7.33.
4.1.1.5. (E/Z)-5-((1H-Indole-3-yl)methylene)-3-(2-(4-chlorophenyl)-
2-oxoethyl)-thiazolidine-2,4-dione (13). Compound 13 was prepared
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0.2 g) and indole-3-carboxaldehyde (0.74 mmol, 0.107 g). Rf =
0.53, m.p. 268–270 1C (0.180 g, 60% yield). FTIR (KBr, n, cm1):
3393, 1731, 1695, 1662, 1589. 1H NMR (400 MHz, DMSO-d6):
d ppm 5.29 (s, 2H), 7.37 (dd, J = 8.6 Hz, J = 1.6 Hz, 1H), 7.48
(d, J = 8.8 Hz, 2H), 7.59 (d, J = 7.2 Hz, 1H), 7.62 (s, 1H), 7.72–7.76
(m, 1H), 7.90 (s, 1H), 8.09 (d, J = 1.6 Hz, 2H), 8.26 (s, 1H), 12.35
(brd s, 1H). 13C NMR (DMSO-d6): d ppm 47.74, 110.10, 113.93,
114.08, 114.39, 121.26, 125.76, 126.25, 128.23, 128.64, 129.01,
130.29, 133.84, 134.38, 134.98, 164.97, 166.77, 191.49. MS (ESI+)
m/z: 397. Anal. calcd for C20H13ClN2O3S: C, 60.53; H, 3.30;
N, 7.06; S, 8.08; found: C, 60.86; H, 3.30; N, 7.28; S, 8.24.
4.1.1.6. (E/Z)-5-((5-Methoxy-1H-indole-3-yl)methylene)-3-(2-(4-
chlorophenyl)-2-oxoethyl)-thiazolidine-2,4-dione (14). Compound
14 was prepared according to the general method starting
from 3-(2-(4-chlorophenyl)-2-oxoethyl)-thiazolidine-2,4-dione
(0.74 mmol, 0.2 g) and 5-methoxy-indole-3-carboxaldehyde
(0.74 mmol, 0.129 g). Rf = 0.46, m.p. 222–224 1C (0.134 g,
62% yield). FTIR (KBr, n, cm1): 3311, 1718, 1686, 1669, 1578.
1H NMR (400 MHz, DMSO-d6): d ppm 3.81 (s, 3H), 5.28 (s, 2H),
6.87 (dd, J = 9.0 Hz, J = 1.6 Hz, 1H), 7.39 (d, J = 8.4 Hz, 1H),
7.47 (d, J = 2.0 Hz, 1H), 7.65 (d, J = 2.0 Hz, 1H), 7.67 (d, J =
1.6 Hz, 1H), 7.89 (s, 1H), 8.09 (d, J = 2.0 Hz, 1H), 8.10 (s, 1H),
8.27 (s, 1H), 12.10 (brd s, 1H). 13C NMR (DMSO-d6): d ppm
47.66, 55.47, 100.27, 110.45, 112.31, 113.25, 113.48, 127.11,
127.68, 129.16, 129.48, 130.19, 131.05, 132.57, 139.33, 155.10,
165.05, 166.92, 190.82. MS (ESI+) m/z: 427. Anal. calcd for
C21H15ClN2O4S–0.9H2O: C, 56.92; H, 3.82; N, 6.32; S, 7.23;
found: C, 56.63; H, 3.63; N, 6.42; S, 7.28.
4.1.1.7. (E/Z)-5-((5-Chloro-1H-indole-3-yl)methylene)-3-(2-(4-chloro-
phenyl)-2-oxoethyl)-thiazolidine-2,4-dione (15). Compound 15 was
prepared according to the general method starting from 3-(2-
(4-chlorophenyl)-2-oxoethyl)-thiazolidine-2,4-dione (0.74 mmol,
0.2 g) and 5-chloro-indole-3-carboxaldehyde (0.74 mmol,
0.132 g). Rf = 0.42, m.p. 243–245 1C (0.110 g, 34% yield). FTIR
(KBr, n, cm1): 3296, 1723, 1669, 1586. 1H NMR (400 MHz,
DMSO-d6): d ppm 5.29 (s, 2H), 7.26 (dd, J = 8.8 Hz, J = 2.0 Hz,
1H), 7.53 (d, J = 8.4 Hz, 1H), 7.67 (d, J = 8.8 Hz, 2H), 7.91 (s, 1H),
8.07–8.11 (m, 3H), 8.26 (s, 1H). 13C NMR (DMSO-d6): d ppm
47.62, 110.16, 113.95, 118.16, 123.15, 125.93, 126.24, 127.99,
129.08, 130.09, 130.43, 132.53, 134.69, 139.27, 164.88, 166.68,
190.67. MS (ESI+) m/z: 431. Anal. calcd for C20H12Cl2N2O3S–
0.4H2O: C, 54.78; H, 2.94; N, 6.38; S, 7.31; found: C, 54.69; H,
3.10; N, 6.67; S, 7.17.
4.1.1.8. (E/Z)-5-((5-Bromo-1H-indole-3-yl)methylene)-3-(2-(4-
chlorophenyl)-2-oxoethyl)-thiazolidine-2,4-dione (16). Compound
16 was prepared according to the general method starting
from 3-(2-(4-chlorophenyl)-2-oxoethyl)-thiazolidine-2,4-dione
(0.74 mmol, 0.2 g) and 5-bromo-indole-3-carboxaldehyde
(0.74 mmol, 0.165 g). Rf = 0.44, m.p. 242–245 1C (0.120 g,
34% yield). FTIR (KBr, n, cm1): 3309, 1723, 1686, 1671, 1586.
1H NMR (400 MHz, DMSO-d6): d ppm 5.27 (s, 2H), 7.36 (d, J =
8.8 Hz, 1H), 7.48 (d, J = 8.4 Hz, 1H), 7.64 (d, J = 8.8 Hz, 2H),
7.87 (s, 1H), 8.08 (d, J = 8.0 Hz, 2H), 8.21 (d, J = 2.4 Hz, 2H),
12.30 (brd s, 1H). 13C NMR (DMSO-d6): d ppm 47.53, 110.06,
113.92, 113.96, 114.30, 121.07, 125.68, 126.09, 128.56, 129.01,
129.99, 130.13, 132.46, 134.92, 139.30, 164.84, 166.62, 190.51.
MS (ESI+) m/z: 475. Anal. calcd for C20H12BrClN2O3S–
0.35H2O: C, 49.83; H, 2.65; N, 5.81; S, 6.65; found: C, 49.87;
H, 2.66; N, 5.99; S, 6.87.
4.1.1.9. (E/Z)-5-((5-Methoxy-1H-indole-3-yl)methylene)-3-(2-(3-
nitrophenyl)-2-oxoethyl)-thiazolidine-2,4-dione (17). Compound
17 was prepared according to the general method starting
from 3-(2-(3-nitrophenyl)-2-oxoethyl)-thiazolidine-2,4-dione
(0.71 mmol, 0.2 g) and 5-methoxy-indole-3-carboxaldehyde
(0.71 mmol, 0.124 g). Rf = 0.22, m.p. 286–288 1C (0.054 g,
17% yield). FTIR (KBr, n, cm1): 3399, 1735, 1712, 1671, 1608.
1H NMR (400 MHz, DMSO-d6): d ppm 3.80 (s, 3H), 5.42 (s, 2H),
7.24 (dd, J = 8.8 Hz, J = 2.0 Hz, 1H), 7.51 (d, J = 8.4 Hz, 1H),
7.86–7.90 (m, 2H), 8.06 (d, J = 2.0 Hz, 1H), 8.25 (s, 1H), 8.49–
8.54 (m, 2H), 8.74–8.75 (m, 1H), 12.34 (s, 1H). 13C NMR
(DMSO-d6): d ppm 47.85, 55.39, 110.28, 113.80, 113.92,
118.20, 122.67, 123.15, 125.90, 126.37, 127.98, 128.38, 130.46,
130.74, 134.42, 134.64, 134.89, 148.04, 164.80, 166.64, 190.64. MS
(ESI) m/z: 437 Anal. calcd for C21H15N3O6S–0.4H2O: C, 56.72;
H, 3.58; N, 9.45; S, 7.21; found: C, 56.52; H, 3.67; N, 9.58; S, 7.39.
4.1.1.10. (E/Z)-5-((5-Chloro-1H-indole-3-yl)methylene)-3-(2-(3-
nitrophenyl)-2-oxoethyl)-thiazolidine-2,4-dione (18). Compound
18 was prepared according to the general method starting from
3-(2-(3-nitrophenyl)-2-oxoethyl)-thiazolidine-2,4-dione (0.71 mmol,
0.2 g) and 5-chloro-indole-3-carboxaldehyde (0.71 mmol, 0.127 g).
Rf = 0.20, m.p. 303–306 1C (0.116 g, 36% yield). FTIR (KBr,
n, cm1): 3404, 1733, 1710, 1671, 1610. 1H NMR (400 MHz,
DMSO-d6): d ppm 5.41 (s, 2H), 6.85 (dd, J = 9.0 Hz, J = 2.4 Hz,
1H), 7.38 (d, J = 8.8 Hz, 1H), 7.46 (d, J = 2.4 Hz, 1H), 7.78 (s, 1H),
7.88 (t, 1H), 8.27 (s, 1H), 8.49–8.54 (m, 2H), 8.75 (t, 1H), 12.10 (brd
s, 1H). 13C NMR (DMSO-d6): d ppm 47.81, 100.20, 110.37, 112.14,
113.17, 113.41, 122.67, 127.16, 127.62, 128.37, 129.45, 130.75,
130.97, 134.41, 134.93, 148.05, 155.04, 164.92, 166.80, 190.70.
MS (ESI+) m/z: 440. Anal. calcd for C20H12ClN3O5S: C, 54.37; H,
2.74; N, 9.51; S, 7.26; found: C, 53.95; H, 2.78; N, 9.62; S, 7.39.
4.1.1.11. (E/Z)-5-((5-Bromo-1H-indole-3-yl)methylene)-3-(2-(3-
nitrophenyl)-2-oxoethyl)-thiazolidine-2,4-dione (19). Compound
19 was prepared according to the general method starting from
3-(2-(3-nitrophenyl)-2-oxoethyl)-thiazolidine-2,4-dione (0.71 mmol,
0.2 g) and 5-bromo-indole-3-carboxaldehyde (0.71 mmol, 0.159 g).
Rf = 0.21, m.p. 311–314 1C (0.119 g, 34% yield). FTIR (KBr,
n, cm1): 3356, 1731, 1709, 1671, 1608. 1H NMR (400 MHz,
DMSO-d6): d ppm 5.44 (s, 2H), 7.37 (dd, J = 9.0 Hz, J = 1.6 Hz,
1H), 7.48 (d, J = 8.4 Hz, 1H), 7.90 (t, 2H), 8.22 (d, J = 1.6 Hz, 1H),
8.27 (s, 1H), 8.51–8.56 (m, 2H), 8.77 (s, 1H). 13C NMR (DMSO-d6):
d ppm 47.90, 110.08, 113.94, 114.39, 121.24, 122.72, 125.75,
126.41, 128.42, 128.63, 130.34, 130.79, 134.46, 134.97, 148.11,
164.85, 166.68, 190.68. MS (ESI+) m/z: 486. Anal. calcd for
C20H12BrN3O5S: C, 49.40; H, 2.49; N, 8.64; S, 6.59; found: C,
49.16; H, 2.62; N, 8.84; S, 6.65.
4.1.1.12. (E/Z)-5-((1H-Indole-3-yl)methylene)-3-(2-(3-methoxy-
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was prepared according to the general method starting from 3-(2-
(3-methoxyphenyl)-2-oxoethyl)-thiazolidine-2,4-dione (0.75 mmol,
0.2 g) and indole-3-carboxaldehyde (0.75 mmol, 0.108 g). Rf =
0.37, m.p. 243–246 1C (0.082 g, 27% yield). FTIR (KBr, n, cm1):
3263, 1722, 1694, 1654, 1589. 1H NMR (400 MHz, DMSO-d6): d
ppm 3.83 (s, 3H), 5.26 (s, 2H), 7.17–7.30 (m, 3H), 7.48–7.55 (m, 3H),
7.66 (d, J = 8.0 Hz, 1H), 7.84 (s, 1H), 7.91 (d, J = 8.0 Hz, 1H), 8.22
(s, 1H), 12.20 (s, 1H). 13C NMR (DMSO-d6): d ppm 47.92, 55.46,
110.42, 112.51, 112.65, 113.22, 118.50, 120.57, 120.68, 121.28,
123.24, 126.54, 126.82, 129.41, 130.25, 135.20, 136.28, 159.56,
165.13, 166.93, 191.43. MS (ESI+) m/z: 392. Anal. calcd for
C21H16N2O4S: C, 64.27; H, 4.11; N, 7.14; S, 8.17; found: C, 64.12;
H, 4.22; N, 7.28; S, 8.27.
4.1.1.13. (E/Z)-5-((1H-Indole-3-yl)methylene)-3-(2-(3,4-dichloro-
phenyl)-2-oxoethyl)-thiazolidine-2,4-dione (21). Compound 21 was
prepared according to the general method starting from 3-(2-
(3,4-dichlorophenyl)-2-oxoethyl)-thiazolidine-2,4-dione (0.65 mmol,
0.2 g) and indole-3-carboxaldehyde (0.65 mmol, 0.094 g). Rf = 0.45,
m.p. 258–260 1C (0.140 g, 49% yield). FTIR (KBr, n, cm1): 3399,
1731, 1697, 1660, 1589. 1H NMR (400 MHz, DMSO-d6): d ppm 5.34
(s, 2H), 7.19–7.29 (m, 2H), 7.52 (d, J = 7.6 Hz, 1H), 7.87–7.94
(m, 3H), 8.03 (dd, J = 8.2 Hz, J = 2.4 Hz, 1H), 8.24 (s, 1H), 8.33 (d, J =
2.4 Hz, 1H), 12.15 (s, 1H). 13C NMR (DMSO-d6): d ppm 48.22,
110.85, 112.94, 113.54, 118.93, 121.72, 123.67, 127.10, 127.25,
128.73, 129.89, 130.79, 131.81, 132.60, 134.45, 136.72, 137.71,
165.47, 167.29, 190.77. MS (ESI+) m/z: 429. Anal. calcd for
C20H12Cl2N2O3S: C, 55.70; H, 2.80; N, 6.50; S, 7.43; found: C,
55.68; H, 2.78; N, 6.69; S, 7.60.
4.1.1.14. (E/Z)-5-((5-Chloro-1H-indole-3-yl)methylene)-3-(2-(3,4-
dichlorophenyl)-2-oxoethyl)-thiazolidine-2,4-dione (22). Compound
22 was prepared according to the general method starting
from 3-(2-(3,4-dichlorophenyl)-2-oxoethyl)-thiazolidine-2,4-dione
(0.65 mmol, 0.2 g) and 5-chloro-indole-3-carboxaldehyde
(0.65 mmol, 0.116 g). Rf = 0.34, m.p. 242–244 1C (0.172 g,
55% yield). FTIR (KBr, n, cm1): 3347, 1727, 1671, 1578.
1H NMR (400 MHz, DMSO-d6): d ppm 5.35 (s, 2H), 7.26 (dd,
J = 8.6 Hz, J = 2.0 Hz, 2H), 7.53 (d, J = 8.8 Hz, 1H), 7.88 (d, J =
8.0 Hz, 1H), 7.92 (s, 1H), 8.03 (dd, J = 8.0 Hz, J = 2.0 Hz, 1H),
8.26 (s, 1H), 8.33 (d, J = 2.0 Hz, 1H), 12.20 (brd s, 1H). 13C NMR
(DMSO-d6): d ppm 47.76, 110.20, 113.88, 113.98, 118.26,
123.21, 125.96, 126.40, 128.04, 128.24, 130.31, 130.51,
131.32, 132.11, 133.95, 134.71, 137.23, 164.87, 166.71,
190.25. MS (ESI+) m/z: 463. Anal. calcd for C20H11Cl3N2O3S:




23 was prepared according to the general method starting
from 3-(2-(3,4-dichlorophenyl)-2-oxoethyl)-thiazolidine-2,4-dione
(0.65 mmol, 0.2 g) and 5-bromo-indole-3-carboxaldehyde
(0.65 mmol, 0.145 g). Rf = 0.35, m.p. 252–254 1C (0.040 g,
12% yield). FTIR (KBr, n, cm1): 3356, 1731, 1684, 1597.
1H NMR (400 MHz, DMSO-d6): d ppm 5.35 (s, 2H), 7.37 (dd,
J = 8.4 Hz, J = 1.6 Hz, 2H), 7.48 (d, J = 8.8 Hz, 1H), 7.87–7.90
(m, 2H), 8.03 (dd, J = 8.2 Hz, J = 2.0 Hz, 1H), 8.27 (s, 1H), 8.33
(d, J = 1.6 Hz, 1H). MS (ESI+) m/z: 507. Anal. calcd for
C20H11BrCl2N2O3S: C, 47.08; H, 2.17; N, 5.49; S, 6.28; found:
C, 46.75; H, 2.43; N, 5.61; S, 6.75.
4.1.1.16. (E/Z)-5-((1H-Indole-3-yl)methylene)-3-(2-(4-fluoro-
phenyl)-2-oxoethyl)-thiazolidine-2,4-dione (24). Compound 24
was prepared according to the general method starting
from 3-(2-(4-fluorophenyl)-2-oxoethyl)-thiazolidine-2,4-dione
(0.79 mmol, 0.2 g) and indole-3-carboxaldehyde (0.79 mmol,
0.114 g). Rf = 0.43, m.p. 263–264 1C, (0.057 g, 19% yield). FTIR
(KBr, n, cm1): 3330, 1727, 1697, 1660, 1591. 1H NMR (400 MHz,
DMSO-d6): d ppm 5.30 (s, 2H), 7.20–7.30 (m, 2H), 7.42–754
(m, 3H), 7.88 (s, 1H), 7.94 (d, J = 7.6 Hz, 1H), 8.17–8.25 (m,
3H), 12.26 (s, 1H). 13C NMR (DMSO-d6): d ppm 47.57, 110.30,
112.39, 113.11, 115.96, 116.18, 118.38, 121.16, 123.13, 126.44,
126.70, 129.30, 130.58 (d, J = 10.8 Hz), 131.35 (d, J = 43.2 Hz),
136.17, 165.01, 166.80, 190.18. MS (ESI+) m/z: 380. Anal. calcd for
C20H13FN2O3S: C, 63.15; H, 3.44; N, 7.36; S, 8.43; found: C, 62.75;
H, 3.58; N, 7.46; S, 8.55.
4.2. Biological activity assays
4.2.1. Cell culture. The MCF-7 human epithelial breast
adenocarcinoma cell line was provided by the SAP Institute
(Ankara, Turkey). The cells were grown in RPMI-1640 medium
(Biological Industries, Israel). The cells were supplemented
with 10% fetal bovine serum stabilized with 1.5% L-glutamine
and 0.1 mg mL1 gentamicin (Sigma-Aldrich, USA) in a 5% CO2
incubator at 37 1C.
4.2.2. Cytotoxicity assay. An xCELLingence Real Time
Quantitative Cell Analyzer (Agilent, USA) was used for cytotoxi-
city analysis. Real-time cell viability analysis was performed on
16-well plates especially designed for the device. The center of
the system is an integrated microelectronic cell sensor array at
the bottom of specially manufactured well plates. The unitless
cell index (CI) was used to measure the relative change in
electrical impedance indicating the cell state. Briefly, cells were
seeded in 16-well plates at a density of 10  103 cells per well in
200 mL of complete medium and allowed to grow overnight for
attachment onto the wells. Then the cells were treated with
three different concentrations (5 mM, 50 mM and 100 mM) of the
compounds for a period of 72 h. Vincristine (1 mM) was used as
a positive control.
4.2.3. Calculation of the IC50 value of selected candidate
compounds. Three candidate compounds that were found to
have significant cytotoxic effects with respect to the positive
control were selected and MCF-7 cells were incubated with 7
different doses for each compound in order to determine the
IC50 values. Cell index results and doses were plotted and IC50
values were calculated for each line equation. Further studies
were continued with these three compounds.
4.2.4. Gene expression analysis
4.2.4.1. RNA isolation. MCF-7 cells were treated with the
determined IC50 doses of the selected candidate compounds
and vincristine (1 mM) as a positive control. Untreated MCF-7
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incubated in a carbon dioxide incubator for 72 hours. RNA was
isolated from the cells with a High Pure RNA Isolation Kit
(Roche Life Sciences) according to the manufacturer’s instruc-
tions. The concentrations and purity of the RNA samples were
determined using an AlphaSpecTM (Alpha Innotech) spectro-
photometer. Absorbance values of RNA samples with an OD260/
OD280 ratio of 1.8–2.0 were selected, which indicates high
purity.
4.2.4.2. cDNA synthesis. RNA samples with an adjusted
concentration of 1000 ng for all groups and free of protein
contamination were used for cDNA synthesis. cDNAs were
synthesized from total RNA by using a random hexamer of a
Transcriptor High Fidelity cDNA Synthesis Kit (Roche Life
Sciences) according to the manufacturer’s instructions.
4.2.4.3. Quantitative real time polymerase chain reaction (qRT-
PCR). PCR assays (RealTime ready Custom qPCR Assays, Roche
Life Sciences) were performed on 96-well plates using the qRT-
PCR method by using a Roche Light Cyclers 480 instrument.
Primer selections were made for the selected 45 genes (ABCB1,
ABCG2, GSTP1, ABCC1, TUBD1, TUBB6, MAP7, MAP1A,
MAP1B, MAP4, ABCG1, ESR1, IGFBP2, BIRC3, STAT1, TNF,
BAX, EGFR, FAS, WNT1, NOTCH1, MYC, PDCD10, PDCD6,
BCL-2, MCL-1, DAPK1, CASP4, TNFRSF11B, TNFRSF10D,
TNFRSF6B, TP53, CASP9, RB1, BRIP1, BARD1, CDKN2A,
CDK4, CDK6, ABL1, CHEK1, FGF2, BRCA2, E2F1, and BRCA1).
Each array is designed to allow duplicate work. The house-
keeping genes (GAPDH, G6PD and ACTB) in the array were used
for normalization of gene expression analysis. The plate design
is given in Table 4.
4.2.4.4. Statistical analysis. qRT-PCR analysis was performed
in duplicate for each group. Relative amount changes were
determined by calculating Ct values (2DDCt) obtained for
each gene. According to this method, from the Ct value of a
gene relative to the control gene (mean Ct value of house-
keeping genes) in the treated cell line, by subtracting the Ct
value of the same gene compared to the control gene in the
untreated line, the value of DDCt [DDCt = DCt treated  DCt
untreated] was obtained. The fold change in the amount of the
gene was obtained by substituting the DDCt value in the
expression 2DDCt. The results obtained with two replicates
were evaluated with the SPSS 16.0 program, and the differences
with p values less than 0.05 and those with more or less 2-fold
changes in gene expression levels were considered as ‘‘statisti-
cally significant’’.
4.3. Materials and methods
Thin Layer Chromatography (TLC) was used to observe the
course of the synthesis reactions and to determine the purities
of the products. As a stationary phase Kieselgel-60 GF254
coated aluminum plates (Merck) and UV light at a 254 nm
wavelength (Camag UV lamp) were used. Silicagel 60 (0.040–
0.060 mm; 230–400 mesh) was used for column chromatogra-
phy. Melting points were determined with Electrothermal 9100
capillary melting point apparatus (Electrothermal, Essex, UK)
and are uncorrected. Mass spectra based on the ESI(+) method
using a Waters ZQ micromass LC-MS spectrometer (Waters
Corporation, Milford, MA, USA) were recorded. The 1H NMR
and 13C NMR spectra were detected in DMSO-d6 using a Varian
Mercury-400 FT-NMR spectrometer (Varian Inc., Palo Alto, CA,
USA), and for the elemental analysis we used a LECO 932 CHNS
(Leco-932, St. Joseph, MI, USA) instrument.
5. Computational methods
5.1. Molecular docking
The structure file for cyclin-dependent kinase 6 (CDK6) (PDB
ID: 5L2I, resolution: 4.10 Å) was obtained from the RCSB
protein database website.53 AutoDockTools 1.5.6. was used for
deleting water molecules and defining the grid box.54 After this
process, polar hydrogens and Gasteiger charges were added
and the grid was also prepared using the same software. The
center coordinates for the assigned grid were x = 89, y = 72.142,
z = 14.42 and the dimensions were x = 40, y = 40, z = 40. The
spacing was defined as 0.375 Å. The 2D structures of the
compounds were drawn on ChemDraw Ultra 12.0, and mini-
mized with the MMFF94 and UFF forcefields (number of steps:
Table 4 PCR array design and genes in the array
1 2 3 4 5 6 7 8 9 10 11 12
A ABCB1 ABCG2 GSTP1 ABCC1 TUBD1 TUBB6 ABCB1 ABCG2 GSTP1 ABCC1 TUBD1 TUBB6
H. sapiens H. sapiens H. sapiens H. sapiens H. sapiens H. sapiens H. sapiens H. sapiens H. sapiens H. sapiens H. sapiens H. sapiens
B MAP7 MAP1A MAP1B MAP4 ABCG1 ESR1 MAP7 MAP1A MAP1B MAP4 ABCG1 ESR1
H. sapiens H.sapiens H. sapiens H. sapiens H. sapiens H. sapiens H. sapiens H. sapiens H. sapiens H. sapiens H. sapiens H. sapiens
C IGFBP2 BIRC3 STAT1 TNF BAX EGFR IGFBP2 BIRC3 STAT1 TNF BAX EGFR
H. sapiens H. sapiens H. sapiens H. sapiens H. sapiens H. sapiens H. sapiens H. sapiens H. sapiens H. sapiens H. sapiens H. sapiens
D FAS WNT1 NOTCH1 MYC PDCD10 PDCD6 FAS WNT1 NOTCH1 MYC PDCD10 PDCD6
H. sapiens H. sapiens H. sapiens H. sapiens H. sapiens H. sapiens H. sapiens H. sapiens H. sapiens H. sapiens H. sapiens H. sapiens
E BCL2 MCL1 DAPK1 CASP4 TNFRSF11B TNFRSF10D BCL2 MCL1 DAPK1 CASP4 TNFRSF11B TNFRSF10D
H. sapiens H. sapiens H. sapiens H. sapiens H. sapiens H. sapiens H. sapiens H. sapiens H. sapiens H. sapiens H. sapiens H. sapiens
F TNFRSF6B TP53 CASP9 RB1 BRIP1 GAPDH TNFRSF6B TP53 CASP9 RB1 BRIP1 GAPDH
H. sapiens H. sapiens H. sapiens H. sapiens H. sapiens H. sapiens H. sapiens H. sapiens H. sapiens H. sapiens H. sapiens H. sapiens
G BARD1 CDKN2A CDK4 CDK6 ABL1 G6PD BARD1 CDKN2A CDK4 CDK6 ABL1 G6PD
H. sapiens H. sapiens H. sapiens H. sapiens H. sapiens H. sapiens H. sapiens H. sapiens H. sapiens H. sapiens H. sapiens H. sapiens
H CHEK1 FGF2 BRCA2 E2F1 BRCA1 ACTB CHEK1 FGF2 BRCA2 E2F1 BRCA1 ACTB
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5000 with the steepest descent algorithm and a convergence
value of 10e–7) and then these files were converted to pdb files
using Avogadro software.55 Subsequently, Gasteiger charges
and torsion were added to the ligand files with AutoDockTools.
The prepared ligands were docked with AutoDock Vina,56 and
interaction diagrams and binding modes were created and
interpreted using the Discovery Studio Visualizer v19.1.0.18287
Ligand Interaction module.57
5.2. Docking validation
The process for validation was implemented before the screening
of the indole-thiazolidinedione derivatives. After determining the
grid coordinates at the beginning of the docking, palbociclib was
re-docked with 5L2I to compare the interactions to the original
complex and to calculate the RMSD between the two aligned
poses. The binding conformer of palbociclib was extracted from
the crystallographic complex of CDK6 (PDB ID: 5L2I, resolution:
4.10 Å) as a reference entry for the RMSD calculation and this
compound was prepared with AutoDockTools for creating charge
and torsion properties. Finally, it was re-docked with the CDK6
protein file and was used in comparison with the original
co-ligand.pdbqt file. The relevant interaction comparisons are
given in Fig. 3. Moreover, the RMSD value for this docking
process was found by using the COMPARE web server, which
aligns two docking poses to calculate the standard, Hungarian
(symmetry-corrected RMSD), and minimum-distance RMSD.58
In this study, the type of RMSD was defined as the symmetry-
corrected RMSD since this method gives the most reliable and
meaningful results.59
5.3. Determination of the ADME properties
For the calculation of the ADME properties of the indole-
thiazolidinedione derivatives, SMILES notations were gener-
ated with the ACD/ChemSketch program. SMILES codes for
the commercialized compounds were procured from PubChem.
Consequently, all of them were submitted as input to the
SwissADME online program, and molecular parameters such
as log P, permeation through the BBB, P-glycoprotein substrate
characteristics, the topological polar surface area, and accor-
dance with the Lipinski filter were evaluated.60 In addition the
CYP-450 enzyme inhibition was calculated with this program
to identify candidates that have a tendency towards drug
interactions.
6. Conclusions
The results obtained in this study indicate that, unlike vincristine,
our compounds tend to lead the cells to apoptosis by increasing
apoptotic gene expression and also suppressing CDK6 expression.
Compounds 10, 15, and 18 have a serious cytotoxic effect on
MCF-7 cells, which is a breast cancer cell line, through apop-
tosis and the cell cycle. However, among them, 15 and 18 have
an effect on decreasing the CDK6 expression levels signifi-
cantly. Moreover, the adequate binding energies and abundant
interactions of these compounds with the CDK6 protein
confirmed this inhibition. SAR analysis from a previous study
suggested several modifications in a similar scaffold to increase
anticancer activity and our results were in line with these
findings. All of our compounds have an unsubstituted nitrogen
atom that increases the H-bonding. We have blocked the
nitrogen of the thiazolidine ring and investigated the effect of
introducing two additional oxo groups on the H-bonding
properties. Finally, we have analyzed their biological activity
results, genomics, and molecular docking fingerprints to grasp
their SAR profiles. Compound 15 has two chloro groups, one of
them at the fifth position of the indole moiety and the other at
the para position of the terminal phenyl. Compound 18 also
has a chloro group at the fifth position of the indole, but this
time the p-chloro group was substituted with an m-nitro group.
However, according to the docking results, the latter has
also increased H-bonding phenomenally. In hindsight, these
substitutions may have increased the cytotoxicity and gene
suppressing characteristics of our derivatives and were in
agreement with the SAR studies that were conducted before.36
By studying the anticancer activities of these compounds in
different cancer and healthy cell lines, at the protein level, and
in in vivo animal experiments, broader and detailed data on
this subject will be obtained. In this respect, the outputs from
this study lead to new studies in the future.
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